The effects of vigabatrin on attention, concentration and mood: an investigation in healthy volunteers.
Ten healthy volunteers (six males; four females) completed this double-blind, crossover design study of vigabatrin vs placebo. Subjects were tested on four occasions; at the baselines of the placebo and the vigabatrin phase, and two weeks thereafter. At time of testing, the dose of vigabatrin was 2 g daily. Changes in cognition were assessed using the Sternberg, the PASAT, the Stroop, and Critical Fusion Flicker tests. Mood was assessed with the Mood Adjective Check List, the Beck Depression Inventory, and the Irritability, Depression and Anxiety scales. We found one drug, and one placebo, related significant difference on a measure of cognition.
Institute of Neurology, London, U.K.
L
L
Thomas
M
M
Trimble
D000328:Adult; D000339:Affect / Q000187:drug effects*; D000927:Anticonvulsants / Q000494:pharmacology*; D001288:Attention / Q000187:drug effects*; D018592:Cross-Over Studies; D004193:Discrimination Learning / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D005425:Flicker Fusion / Q000187:drug effects; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D011340:Problem Solving / Q000187:drug effects; D012684:Sensory Thresholds / Q000187:drug effects; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology
D000927:Anticonvulsants; D005680:gamma-Aminobutyric Acid; D020888:Vigabatrin